Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Atai Life Sciences N.V. (NQ: ATAI )

1.300 -0.040 (-2.99%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 295,634
Open 1.340
Bid (Size) 1.300 (1)
Ask (Size) 1.330 (20)
Prev. Close 1.340
Today's Range 1.290 - 1.340
52wk Range 1.140 - 3.650
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Psyched: Steve Cohen Goes Big On Cybin, Fed Intervention On Psilocybin, Ketamine Insurance And More
Billionaire Steve Cohen Buys 19M Shares Of Cybin Stock For Psychedelics R&D, Blake Mycoskie $100M Pledge 
Via Benzinga
Topics Economy
Exposures Interest Rates
Psychedelic Drug Stocks Dragged Down By 83% Collapse In SEEL Stock Price
With the 82.6% collapse of Seelos Therapeutics (SEEL) last week, the 6 psychedelic-compound-based research & development stocks in our Psychedelic Drug Stocks Index declined by 13.0%, on average, and... 
Via Talk Markets

Performance

YTD
-50.94%
-50.94%
1 Month
-17.72%
-17.72%
3 Month
-20.73%
-20.73%
6 Month
-18.24%
-18.24%
1 Year
-61.65%
-61.65%

More News

Read More
Exclusive Insights: How Tech Leaders Are Finding Balance Through Microdosing Psychedelics
Via Benzinga
The Breakthrough Therapy Aiming To Solve The World’s Mental Health Crisis
Via FinancialNewsMedia
Topics Economy
Exposures Economy Product Safety
Psyched: MDMA Trials For PTSD, Congressional Amendments, Scotland's Consumption Site & More
Via Benzinga
Exposures Product Safety
Billionaire Steve Cohen Invests $19M In Cybin For Psychedelics R&D, Blake Mycoskie's $100M Pledge Update
Via Benzinga
4 Of The 6 Largest Psychedelic Compound-Based R & D Stocks Had A Good Week
Via Talk Markets
atai Life Sciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
From atai Life Sciences
Via GlobeNewswire
NY Consulting Firm Predicts Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years
Via Benzinga
Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
6 Largest Psychedelic Compound-Based R & D Stocks In Decline
Via Talk Markets
atai Life Sciences to Participate in Upcoming September Investor Conferences
From atai Life Sciences
Via GlobeNewswire
6 Largest Psychedelic Compound-Based R & D Stocks Up 4%, On Average, Last Week
Via Talk Markets
Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More
Via Benzinga
August Recap: Largest Psychedelic Compound-Based R & D Stocks Down 15%
Via Talk Markets
Psyched: Psilocybin For Gambling Addiction, Ex-NHL Player's Retreat, Fellini's LSD Creativity, Surveys, Financing & More
Via Benzinga
6 Largest Psychedelic Compound-Based R&D Stocks Continued Downwards, On Average, This Week
Via Talk Markets
Psyched: Fed Study On Psychedelics, Janet Yellen's Magic Mushrooms, Financing Deals & Quarterly Reports
Via Benzinga
Topics Cannabis Economy
Exposures Cannabis Interest Rates
Largest Psychedelic Compound-Based R&D Stocks Continue Downward Trend
Via Talk Markets
Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
Via Benzinga
So Far, August Isn't Kind To 4 Of 6 Constituents In Our Psychedelic Drug Stocks Index
Via Talk Markets
Atai's Q2 2023 Plus Clinical Data On Ibogaine-Opioid Study, Pipeline's Psilocybin, DMT, Ketamine & MDMA
Via Benzinga
atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine)
From atai Life Sciences
Via GlobeNewswire
Atai's Clinical Results Of R-Ketamine For Depression: Road To Subcutaneous At-Home Administration
Via Benzinga
atai Life Sciences Announces Results from the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)
From atai Life Sciences
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.